Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.)
245 First Street
Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. Sarepta is also developing therapeutics for the treatment of rare, infectious and other diseases.
Formerly called Antivirals, Inc.
CEO: Ed Kaye, M.D.
Please click here for clinical trial information.